Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial
(2023)
Journal Article
Gunn, D., Topan, R., Fried, R., Holloway, I., Brindle, R., Hartley, S., …Spiller, R. (2023). Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial. Efficacy and Mechanism Evaluation, 10(9), 1-154. https://doi.org/10.3310/ytfw7874
Background: Irritable bowel syndrome with diarrhoea is characterised by frequent, loose or watery stools with associated urgency, resulting in marked reduction of quality of life. Ondansetron, a 5-hydroxytryptamine-3 receptor antagonist, has been sho... Read More about Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial.